TW202237075A - 抑制小兒近視進展用點眼劑及小兒近視進展抑制劑之篩選方法 - Google Patents

抑制小兒近視進展用點眼劑及小兒近視進展抑制劑之篩選方法 Download PDF

Info

Publication number
TW202237075A
TW202237075A TW110132525A TW110132525A TW202237075A TW 202237075 A TW202237075 A TW 202237075A TW 110132525 A TW110132525 A TW 110132525A TW 110132525 A TW110132525 A TW 110132525A TW 202237075 A TW202237075 A TW 202237075A
Authority
TW
Taiwan
Prior art keywords
myopia
pathway
eye
children
atf6
Prior art date
Application number
TW110132525A
Other languages
English (en)
Chinese (zh)
Inventor
坪田一男
栗原俊英
池田真一
森紀和子
姜效炎
Original Assignee
日商坪田實驗室股份有限公司
日商樂敦製藥股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 日商坪田實驗室股份有限公司, 日商樂敦製藥股份有限公司 filed Critical 日商坪田實驗室股份有限公司
Publication of TW202237075A publication Critical patent/TW202237075A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058—Neurological cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurology (AREA)
TW110132525A 2020-12-11 2021-09-01 抑制小兒近視進展用點眼劑及小兒近視進展抑制劑之篩選方法 TW202237075A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2020205489 2020-12-11
JP2020-205489 2020-12-11

Publications (1)

Publication Number Publication Date
TW202237075A true TW202237075A (zh) 2022-10-01

Family

ID=81973514

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110132525A TW202237075A (zh) 2020-12-11 2021-09-01 抑制小兒近視進展用點眼劑及小兒近視進展抑制劑之篩選方法

Country Status (15)

Country Link
US (1) US20240041806A1 (https=)
EP (1) EP4257147A4 (https=)
JP (1) JPWO2022123836A1 (https=)
KR (1) KR20230135054A (https=)
CN (1) CN116761595A (https=)
AU (1) AU2021396680A1 (https=)
CA (1) CA3204753A1 (https=)
CL (1) CL2023001634A1 (https=)
IL (1) IL303499A (https=)
MA (1) MA61683A1 (https=)
MX (1) MX2023006723A (https=)
PE (1) PE20240227A1 (https=)
TN (1) TN2023000138A1 (https=)
TW (1) TW202237075A (https=)
WO (1) WO2022123836A1 (https=)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020509085A (ja) * 2017-02-21 2020-03-26 シンガポール ヘルス サービシーズ プライベート リミテッド アトロピンを含む、近視の発症を予防するまたは遅らせるための組成物および方法
JP6637217B2 (ja) * 2017-03-06 2020-01-29 株式会社坪田ラボ 近視予防又は抑制剤、マウス近視誘導モデルの作製方法、及び、近視予防又は抑制医薬スクリーニング方法
CN107898793B (zh) * 2017-12-01 2019-12-24 温州医科大学 一种抑制近视的方法及制备药物的应用
KR102902220B1 (ko) * 2018-12-18 2025-12-18 산텐 세이야꾸 가부시키가이샤 4-페닐부티르산을 함유하는 노시의 치료 또는 예방제

Also Published As

Publication number Publication date
WO2022123836A1 (ja) 2022-06-16
IL303499A (en) 2023-08-01
AU2021396680A9 (en) 2024-05-30
CL2023001634A1 (es) 2024-02-02
MX2023006723A (es) 2023-09-21
US20240041806A1 (en) 2024-02-08
CA3204753A1 (en) 2022-06-16
KR20230135054A (ko) 2023-09-22
PE20240227A1 (es) 2024-02-16
EP4257147A4 (en) 2024-11-06
CN116761595A (zh) 2023-09-15
TN2023000138A1 (en) 2025-01-02
JPWO2022123836A1 (https=) 2022-06-16
AU2021396680A1 (en) 2023-07-06
EP4257147A1 (en) 2023-10-11
MA61683A1 (fr) 2023-08-31

Similar Documents

Publication Publication Date Title
JP7116490B2 (ja) 眼の炎症性障害および疾患の組合せ処置
CA3023149C (en) AQUEOUS COMPOSITION CONTAINING ATROPINE
Porela‐Tiihonen et al. Recovery after cataract surgery
AU2018348174A1 (en) Treatment of inflammatory disorders
KR20140076587A (ko) 노안, 경도 원시 및 불규칙한 난시의 치료를 위한 조성물 및 방법
TWI815423B (zh) 用於治療近視的方法和藥物組合物
AU2021346006A9 (en) Application of regulation of eye sclera lipid metabolism to inhibit myopia
JP7816716B2 (ja) 強膜菲薄化治療用点眼剤及び強膜菲薄化治療剤のスクリーニング方法
RU2670100C2 (ru) Офтальмическая композиция для цвиттерионных мягких контактных линз
TW202237075A (zh) 抑制小兒近視進展用點眼劑及小兒近視進展抑制劑之篩選方法
TW202337462A (zh) 採用長春西汀治療近視的方法
RU2677665C2 (ru) Офтальмическая композиция для анионных мягких контактных линз
TWI896143B (zh) 一種有效延緩及治療近視的藥物組合物
RU2669558C2 (ru) Офтальмологическая композиция для цвиттерионных мягких контактных линз
RU2669570C2 (ru) Офтальмологическая композиция для цвиттерионных мягких контактных линз
JP2019094300A (ja) 点眼剤組成物
WO2023145578A1 (ja) 薬剤点眼による近視誘導モデル
JP2025169215A (ja) 結膜充血を改善、緩和又は抑制するための組成物
HK40109101A (zh) 一种有效延缓及治疗近视的药物组合物
CN115645420A (zh) 甘露糖及其药用衍生物在制备预防和/或治疗年龄相关性黄斑变性的药物中的应用
Manjunath Comparitive Study of Efficacy of Preoperative Use of Topical Nepafenac, Ketorolac Tromethamine and Flurbiprofen in Maintenance of Intraoperative Mydriasis for Cataract Surgery: A Randomised Double Blind Study